H.C. Wainwright downgraded Rallybio (RLYB) to Neutral from Buy without a price target after the company announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopena. The firm is surprised by the negative pharmacokinetic data and consider this a “major setback.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Citizens JMP downgrades Rallybio on RLYB212 discontinuation
- Rallybio downgraded to Market Perform from Outperform at Citizens JMP
- Rallybio discontinues RLYB212 program
- Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
- Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating